These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 36579950)

  • 41. Efficiency of antisense oligonucleotide drug discovery.
    Bennett CF
    Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):215-24. PubMed ID: 12162703
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Using RNA-seq to Assess Off-Target Effects of Antisense Oligonucleotides in Human Cell Lines.
    Michel S; Schirduan K; Shen Y; Klar R; Tost J; Jaschinski F
    Mol Diagn Ther; 2021 Jan; 25(1):77-85. PubMed ID: 33314011
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oligonucleotide delivery: a patent review (2010 - 2013).
    Grijalvo S; Aviñó A; Eritja R
    Expert Opin Ther Pat; 2014 Jul; 24(7):801-19. PubMed ID: 24798406
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antisense-based cancer therapeutics: are we there yet?
    Rayburn ER; Wang H; Zhang R
    Expert Opin Emerg Drugs; 2006 May; 11(2):337-52. PubMed ID: 16634705
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synthetic oligonucleotides: the development of antisense therapeutics.
    Monteith DK; Levin AA
    Toxicol Pathol; 1999; 27(1):8-13. PubMed ID: 10367666
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of Intravesical Liposome-Based Nerve Growth Factor Antisense Therapy on Bladder Overactivity and Nociception in a Rat Model of Cystitis Induced by Hydrogen Peroxide.
    Majima T; Tyagi P; Dogishi K; Kashyap M; Funahashi Y; Gotoh M; Chancellor MB; Yoshimura N
    Hum Gene Ther; 2017 Jul; 28(7):598-609. PubMed ID: 28446032
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Managing the sequence-specificity of antisense oligonucleotides in drug discovery.
    Hagedorn PH; Hansen BR; Koch T; Lindow M
    Nucleic Acids Res; 2017 Mar; 45(5):2262-2282. PubMed ID: 28426096
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics.
    Xu L; Anchordoquy T
    J Pharm Sci; 2011 Jan; 100(1):38-52. PubMed ID: 20575003
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antisense technology: an overview and prospectus.
    Crooke ST; Baker BF; Crooke RM; Liang XH
    Nat Rev Drug Discov; 2021 Jun; 20(6):427-453. PubMed ID: 33762737
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antisense therapy for angioplasty restenosis. Some critical considerations.
    Bennett MR; Schwartz SM
    Circulation; 1995 Oct; 92(7):1981-93. PubMed ID: 7671381
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 2'-Modified oligonucleotides for antisense therapeutics.
    Prakash TP; Bhat B
    Curr Top Med Chem; 2007; 7(7):641-9. PubMed ID: 17430205
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antisense and RNAi: powerful tools in drug target discovery and validation.
    Lavery KS; King TH
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):561-9. PubMed ID: 12951819
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical expert panel on monitoring potential lung toxicity of inhaled oligonucleotides: consensus points and recommendations.
    Alton EW; Boushey HA; Garn H; Green FH; Hodges M; Martin RJ; Murdoch RD; Renz H; Shrewsbury SB; Seguin R; Johnson G; Parry JD; Tepper J; Renzi P; Cavagnaro J; Ferrari N
    Nucleic Acid Ther; 2012 Aug; 22(4):246-54. PubMed ID: 22809313
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Thiomorpholino oligonucleotides as a robust class of next generation platforms for alternate mRNA splicing.
    Le BT; Paul S; Jastrzebska K; Langer H; Caruthers MH; Veedu RN
    Proc Natl Acad Sci U S A; 2022 Sep; 119(36):e2207956119. PubMed ID: 36037350
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Progress in antisense oligonucleotide therapeutics.
    Crooke ST; Bennett CF
    Annu Rev Pharmacol Toxicol; 1996; 36():107-29. PubMed ID: 8725384
    [TBL] [Abstract][Full Text] [Related]  

  • 57. International Conference on Harmonisation; addendum to International Conference on Harmonisation Guidance on S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2012 May; 77(97):29665-6. PubMed ID: 22616137
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Introduction to a manuscript series on the characterization and use of microphysiological systems (MPS) in pharmaceutical safety and ADME applications.
    Fabre K; Berridge B; Proctor WR; Ralston S; Will Y; Baran SW; Yoder G; Van Vleet TR
    Lab Chip; 2020 Mar; 20(6):1049-1057. PubMed ID: 32073020
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Is there a future for cell-penetrating peptides in oligonucleotide delivery?
    Lee SH; Castagner B; Leroux JC
    Eur J Pharm Biopharm; 2013 Sep; 85(1):5-11. PubMed ID: 23958313
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology.
    Jepsen JS; Sørensen MD; Wengel J
    Oligonucleotides; 2004; 14(2):130-46. PubMed ID: 15294076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.